How to Get Trulicity in West Virginia: Prescriptions, Telehealth, and Pharmacy Access

What Is Trulicity and Why West Virginia Providers Prescribe It

Trulicity is the brand name for dulaglutide, a once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for adults with type 2 diabetes to improve glycemic control and, in patients with established cardiovascular disease or multiple risk factors, to reduce major adverse cardiovascular events (MACE). [1] West Virginia has one of the highest rates of type 2 diabetes in the United States, with the CDC reporting a diagnosed diabetes prevalence of 15.7% in WV adults as of 2022, compared to a national average of 11.6%. [2] That burden makes dulaglutide a frequently discussed option among WV endocrinologists, primary care physicians, and telehealth clinicians alike.

Dulaglutide works by mimicking endogenous GLP-1 to stimulate glucose-dependent insulin secretion, suppress glucagon release, and slow gastric emptying. [3] The molecule's extended half-life of approximately five days allows once-weekly dosing, which improves adherence compared to daily injectables. [4] The FDA first approved Trulicity in September 2014 for type 2 diabetes and expanded the label in 2020 to include cardiovascular risk reduction based on REWIND trial data. [1]

In the REWIND trial (N=9,901), dulaglutide 1.5 mg once weekly produced a statistically significant 12% relative risk reduction in the composite MACE endpoint (non-fatal MI, non-fatal stroke, or CV death) compared to placebo over a median follow-up of 5.4 years (HR 0.88 to 95% CI 0.79-0.99, P<0.026). [5] That trial enrolled participants with a mean age of 66 years and a mean HbA1c of 7.3%, reflecting a real-world population typical of older WV patients with longstanding diabetes.

A 2021 analysis in Diabetes Care demonstrated that dulaglutide reduced HbA1c by a mean of 1.4 percentage points from baseline at 26 weeks in patients already on metformin, with 55% achieving HbA1c <7.0%. [6]

How to Get a Trulicity Prescription in West Virginia

West Virginia residents have three main routes to a Trulicity prescription: an in-person visit with a primary care physician or endocrinologist, a scheduled telehealth appointment with a WV-licensed provider, or a HealthRX online consultation. Each route requires the same clinical documentation.

The prescribing encounter must establish a diagnosis of type 2 diabetes mellitus (ICD-10: E11.x) or, where appropriate, the cardiovascular risk reduction indication. Your provider will review your current diabetes medications, kidney function, history of pancreatitis, personal or family history of medullary thyroid carcinoma (MTC), and MEN2 syndrome status, because dulaglutide carries an FDA black box warning for thyroid C-cell tumors observed in rodent studies. [1] Patients with a personal or family history of MTC or MEN2 should not receive dulaglutide.

The WV Board of Medicine permits telehealth prescribing of controlled and non-controlled medications when the provider establishes a valid patient-provider relationship, which for non-controlled drugs like dulaglutide may occur via synchronous audio-video visit without a prior in-person examination. [7] That means a fully online visit with a WV-licensed MD, DO, NP, or PA is sufficient to receive a Trulicity prescription, provided you supply your lab results and complete a thorough intake questionnaire.

Labs Required Before Starting Trulicity in West Virginia

Most WV providers require four to six standard labs before writing a dulaglutide prescription, and commercial insurers typically demand these same results for prior authorization approval.

The American Diabetes Association's 2024 Standards of Care specify that HbA1c should be measured at least twice per year in patients meeting treatment goals and quarterly when therapy is being adjusted. [8] Before initiating a new GLP-1 agent, a baseline HbA1c is required. Most WV telehealth platforms also request:

1. Fasting plasma glucose (to confirm diagnosis and set a glycemic baseline)
2. Comprehensive metabolic panel or basic metabolic panel (to assess kidney and liver function; eGFR <15 mL/min/1.73 m² is a caution for dosing)
3. Lipid panel (for cardiovascular risk stratification)
4. TSH if thyroid disease is suspected or prior thyroid history exists [9]
5. Urine albumin-to-creatinine ratio (UACR) per ADA recommendations for diabetic kidney disease screening [8]

The FDA label for dulaglutide does not require dose adjustment for mild-to-moderate renal impairment, but your provider will use eGFR data to guide overall diabetes management decisions. [1] Labs drawn within the past six months are generally acceptable to most prior authorization reviewers, though some WV insurers require results within 90 days.

Telehealth Prescribing for Trulicity in West Virginia

West Virginia is one of the states with relatively open telehealth prescribing rules for non-controlled substances. Under WV Code §30-3-13a and the associated Board of Medicine telemedicine policy, licensed practitioners may prescribe medications after an appropriate evaluation conducted via real-time audio-visual technology. [7]

Telehealth visits for Trulicity in WV typically follow this sequence. First, you complete an online intake form disclosing your diabetes history, current medications, allergies, and any contraindications. Second, you upload or connect lab results from a local draw (Quest, LabCorp, and several independent labs operate across WV, including in Charleston, Huntington, Morgantown, and Martinsburg). Third, a WV-licensed clinician reviews your chart and conducts a synchronous video visit, usually lasting 20 to 30 minutes. Fourth, if dulaglutide is appropriate, the provider sends the prescription electronically to a pharmacy of your choice or a mail-order pharmacy that ships to WV addresses.

The HealthRX clinical team uses a structured four-checkpoint screening protocol before approving any GLP-1 prescription in West Virginia: (1) confirmed T2DM diagnosis with HbA1c documentation, (2) thyroid and pancreatitis history clearance, (3) renal function review with eGFR, and (4) cardiovascular risk stratification using the ASCVD Pooled Cohort Equations. This protocol aligns with ADA 2024 Standards of Care Section 9, which states: "For patients with type 2 diabetes and established cardiovascular disease or indicators of high cardiovascular risk, a GLP-1 receptor agonist with demonstrated cardiovascular benefit is recommended." [8]

A 2023 study in JAMA Network Open found that telehealth-initiated GLP-1 prescriptions had a 30-day fill rate of 71% versus 64% for in-person prescriptions, suggesting that the convenience of remote visits may improve early medication adherence. [10]

Who Can Prescribe Trulicity in West Virginia

In West Virginia, Trulicity may be prescribed by any licensed practitioner with prescriptive authority for non-controlled substances. That group includes:

MDs and DOs hold full prescriptive authority in WV with no collaborative practice agreement required for non-controlled medications. [11]

Advanced Practice Registered Nurses (APRNs) in West Virginia must operate under a collaborative practice agreement with a physician for the first three years of practice. After that period, APRNs with full practice status may prescribe independently under WV Code §30-7-15a. [12]

Physician Assistants (PAs) in WV practice under a supervisory agreement with a physician and may prescribe non-controlled medications within the scope of that agreement under WV Code §30-3E-1. [11]

All three provider types can prescribe dulaglutide via telehealth when practicing within the WV Board of Medicine's telemedicine guidelines. [7] Endocrinologists and primary care physicians with diabetes management experience are the most common prescribers, but WV has a notable shortage of endocrinologists: the state has fewer than 30 practicing endocrinologists for a population of 1.77 million, making telehealth and primary care prescribing especially important. [13]

Prior Authorization for Trulicity in WV: What You Need

Most commercial insurance plans operating in West Virginia require prior authorization (PA) before they will cover Trulicity. The documentation requirements differ by insurer, but the following elements appear in virtually every WV commercial plan's PA criteria.

Required documentation for most WV prior authorizations:

• Confirmed T2DM diagnosis with ICD-10 code
• Most recent HbA1c (typically requiring HbA1c >7.0% or per plan threshold)
• Evidence of metformin trial at maximally tolerated dose (usually 90 days) unless contraindicated
• Evidence of at least one additional first-line agent trial (SGLT-2 inhibitor, sulfonylurea, or DPP-4 inhibitor) unless contraindicated
• Prescriber attestation of cardiovascular risk status (for the cardiovascular indication)
• Body weight and BMI (some plans require BMI >25 kg/m²)

The ADA 2024 Standards state that for patients with type 2 diabetes and established atherosclerotic cardiovascular disease, a GLP-1 receptor agonist or SGLT-2 inhibitor with proven cardiovascular benefit should be prescribed independent of baseline HbA1c. [8] That language from a named guideline document can support a prior authorization appeal if a plan denies coverage solely on HbA1c grounds when the cardiovascular indication is documented.

West Virginia Medicaid (WV DHHR) does not cover Trulicity for type 2 diabetes as of mid-2025. Medicaid enrollees should ask their provider about alternative GLP-1 agents on the WV Medicaid preferred drug list or request a prior authorization exception with clinical justification. Appeals supported by REWIND cardiovascular outcome data have been successful in some WV cases, though no statewide approval rate data are publicly available. [5]

The average PA processing time in WV is five to seven business days for standard review and 72 hours for urgent review. Peer-to-peer review calls between your provider and the insurer's medical director can shorten denial-to-approval time significantly.

Trulicity Pharmacies in West Virginia

Once prescribed, you can fill dulaglutide at any WV-licensed retail or mail-order pharmacy that stocks the medication. Major chains with broad WV coverage include CVS, Walgreens, Kroger Pharmacy, Walmart Pharmacy, and Rite Aid. Independent pharmacies in rural WV counties may need 24 to 48 hours to order Trulicity if they do not carry it in stock, given the drug's cold-chain storage requirements (2°C to 8°C refrigeration). [1]

Mail-order pharmacies that ship to WV addresses include Express Scripts, Optum Rx, CVS Caremark, and several specialty pharmacies contracted with telehealth platforms. Shipping typically adds one to three business days after the prescription is processed, and the medication ships in an insulated, temperature-controlled package with ice packs rated for 48 to 96 hours of transit.

503A compounding pharmacies in West Virginia may compound dulaglutide for individual patients under a valid prescription when the commercially manufactured product is not clinically suitable for a specific patient (for example, due to a documented allergy to an excipient). [14] West Virginia's Board of Pharmacy licenses 503A compounding pharmacies under WV Code §60A-8-1, and these facilities must comply with USP Chapter 797 sterile compounding standards. [15] The FDA's position is that compounding a copy of a commercially available drug is generally not permissible unless there is a specific documented patient need. [14] Patients considering compounded dulaglutide should discuss this with their provider and confirm the pharmacy's WV license status before proceeding.

A 2022 FDA guidance document noted that dulaglutide is not on the FDA's drug shortage list, which limits the justification for routine 503A compounding of the brand-name formulation. [14] Ask your HealthRX provider to document any specific clinical need if you are considering this route.

Transferring a Trulicity Prescription to West Virginia

Transferring a Trulicity prescription to a WV pharmacy is permitted under both federal and WV pharmacy law. Under WV Board of Pharmacy regulations, a licensed pharmacist may transfer a valid prescription for a non-controlled substance from one pharmacy to another, including from an out-of-state pharmacy, provided the prescription has remaining refills and has not expired. [15]

To transfer your prescription, contact the WV pharmacy where you want to fill it, provide the original pharmacy's name and phone number, and the WV pharmacist will initiate the transfer directly. You do not need to contact your prescriber again unless the prescription has expired (Trulicity prescriptions are typically written for one year with monthly or quarterly refills). If your out-of-state provider is not licensed in WV, you will need a new prescription from a WV-licensed provider for ongoing fills after you relocate. Telehealth providers licensed in WV can write that new prescription after a brief clinical review visit. [7]

Patients relocating to WV from states with active prior authorizations should be aware that WV-based insurers will not honor out-of-state PA approvals. A new PA must be submitted to your WV insurer. Build two to four weeks into your relocation timeline for this process.

Dulaglutide Dosing and Starting Expectations for WV Patients

Trulicity is available in four doses: 0.75 mg, 1.5 mg, 3.0 mg, and 4.5 mg, all in single-dose autoinjector pens. [1] Most WV providers start patients at 0.75 mg once weekly for four weeks to allow gastrointestinal tolerance to develop, then titrate to 1.5 mg. The AWARD-1 trial (N=978) showed that the 1.5 mg dose reduced HbA1c by a mean of 1.51 percentage points versus 1.30 percentage points for 0.75 mg at 26 weeks. [16]

Higher doses (3.0 mg and 4.5 mg) were evaluated in the AWARD-11 trial (N=1,842), where dulaglutide 4.5 mg produced a mean HbA1c reduction of 1.77 percentage points and a mean body weight reduction of 4.7 kg at 36 weeks, compared to 1.54 percentage points and 2.7 kg for the 1.5 mg dose. [17] The 4.5 mg dose may be especially relevant for WV patients with both poor glycemic control and obesity, given WV's adult obesity prevalence of 40.6%, the highest in the nation per CDC 2023 data. [2]

The most common side effects are gastrointestinal: nausea (12 to 21% of patients), diarrhea (8 to 14%), vomiting (6 to 12%), and abdominal pain (9%). [1] These effects are typically most pronounced in the first four to eight weeks and attenuate with continued use. Eating smaller meals, avoiding high-fat foods in the first month, and injecting on a consistent weekly schedule all reduce GI burden.

Patients should expect to see their first meaningful HbA1c change at the 12-week mark. A full assessment of glycemic response is typically performed at 26 weeks, consistent with ADA monitoring recommendations. [8]

Cost and Savings Programs for Trulicity in West Virginia

Without insurance coverage, Trulicity's list price is approximately $900 to $1,000 per month for a four-pen supply (four weekly injections). Eli Lilly offers the Trulicity Savings Card for commercially insured patients, which can reduce out-of-pocket cost to as low as $25 per fill for eligible patients. [18] Uninsured WV residents may qualify for Eli Lilly's Insulin Value Program or the Lilly Cares Foundation patient assistance program, which provides Trulicity at no cost to qualifying low-income patients. [18]

GoodRx and similar discount card programs typically list dulaglutide at $700 to $850 at WV retail pharmacies, a reduction from list price but still a substantial monthly expense without insurance support. The WV Insurance Commission operates a prescription drug affordability program that may provide additional guidance for residents struggling with medication costs; their helpline is (888) 879-9842.

Patients whose commercial plans deny prior authorization have the right to appeal under WV Code §33-15E, which requires insurers to provide a written denial with clinical criteria and a clear appeal pathway. [19] A first-level appeal supported by REWIND cardiovascular outcome data and ADA guideline language has an estimated 35 to 45% approval rate based on published appeal outcome data from similar GLP-1 prior authorization studies. [20]